Authorized Sale of a Product Does Not Exhaust Patent Rights Against Upstream Parties in the Chain of Commerce

Apr 4, 2019

Reading Time : 2 min

Perfect ultimately settled with Apple, agreeing not to sue Apple or Apple’s customers for infringement of the asserted patents. That settlement included a carve out excluding from the agreement Perfect’s infringement claims against Adaptics. Adaptics filed a motion for summary judgment alleging that, despite the carve out, Perfect’s settlement with Apple exhausted Perfect’s patent rights in the accused products. If it did not, Perfect could recover twice on the value of its patent. Perfect disagreed, arguing that patent exhaustion only applies to subsequent, downstream purchasers after an initial authorized sale; it does not apply to upstream manufacturers.

The court agreed with Perfect, holding that “because patent exhaustion only applies to the patentee’s rights against downstream transfers, Perfect’s settlement with Apple did not exhaust its rights against Adaptics.” The court characterized Adaptics’ argument as requiring “a novel, upstream-oriented application of patent exhaustion that has no support in case law.” In reaching this conclusion, the court first walked through the Supreme Court’s recent Impression Products, Inc. v. Lexmark International, Inc., 137 S. Ct. 1523, 1532-33 (2017) decision relating to patent exhaustion. The court noted that Adaptics is likely correct that the settlement authorized Apple and all of Apple’s customers to sell products manufactured by Adaptics, exhausting Perfect’s rights against Apple and Apple’s customers. But that was irrelevant to Perfect’s rights against Adaptics itself because Impression Products related to the rights of subsequent owners to use or resell a product. And the other district court cases that considered Adaptics’ upstream patent exhaustion arguments had similarly rejected them.

The court then addressed Adaptics’ argument that Perfect would be recovering twice for the same infringement. The court rejected this theory as well, explaining that Adaptics’ and Apple’s alleged infringement was not the same act of infringement. According to the court, Adaptics’ infringement necessarily occurred before any authorized sales by Apple. And, in any event, when a patentee settles with a downstream distributor, both parties are necessarily aware of the existence of the infringing manufacturer and presumably account for that by limiting the settlement to less than the patent’s full value. Thus, there was no danger that Perfect was recovering twice for the same infringement.

Practice Tip: When negotiating a settlement or developing a reasonable royalty damages theory, parties should always account for the existence of both upstream and downstream links in the chain of commerce. In this case, Apple apparently determined that carving out Adaptics’ conduct from the settlement agreement was in its interest. The lack of upstream patent exhaustion, as the court observed, would tend to support a lower royalty or settlement amount for the reseller. But in other cases, it may be in the reseller’s interest to include the upstream manufacturer in the settlement to insure a continued supply of the accused product.

Perfect Co. v. Adaptics Ltd., 14-cv-3714-RBL (W.D. Was. Mar. 19, 2019) (Dkt. No. 425)

Share This Insight

Previous Entries

IP Newsflash

June 6, 2025

In a precedential opinion, the Federal Circuit definitively held that the Patent Trial and Appeal Board has jurisdiction over IPRs that concern expired patents.

...

Read More

IP Newsflash

June 6, 2025

In a patent infringement litigation in the U.S. District Court for the Eastern District of Texas, Judge Rodney Gilstrap denied a joint motion to stay the litigation pending resolution of inter partes review when it was uncertain that all defendants would be bound by the statutory estoppel provision of 35 U.S.C. § 315(e).

...

Read More

IP Newsflash

May 30, 2025

A district court recently dismissed a patent infringement complaint for improper venue under 28 U.S.C. § 1400(b), finding that the storage and distribution of products from an Amazon warehouse was not sufficient to establish that warehouse as a regular and established place of business in the district.

...

Read More

IP Newsflash

May 27, 2025

The Federal Circuit affirmed a District of Delaware finding of non-infringement in an ANDA litigation due to the patentee’s clear and unmistakable disavowal of claim scope during prosecution. Specifically, the court held that statements made during prosecution of a parent application before the asserted claims were allowed amounted to a prosecution disclaimer that extended to subsequent patents in the family. In reaching this conclusion, the court rejected an attempt by the patentee to resurrect the claim scope through a unilateral, self-serving statement made in later applications in the family.

...

Read More

IP Newsflash

May 13, 2025

The Federal Circuit recently affirmed a district court’s holding that patent term extension (PTE) for a reissued patent was properly based on the issue date of the original patent and not that of the reissued patent. The Federal Circuit concluded that, where both the original and reissued patents claimed a drug product under regulatory review, using the issue date of the original patent to calculate PTE comports with both the purpose of the Hatch-Waxman Act and the related statutory context.

...

Read More

IP Newsflash

May 12, 2025

The Patent Trial and Appeal Board recently declined to institute a petition for IPR that was filed on the same day that the petitioner filed another petition challenging the same claims of the same patent. The board was not persuaded by petitioner’s arguments that a second petition was needed due to alleged claim construction issues or the number, length or scope differences of the challenged claims.

...

Read More

IP Newsflash

May 9, 2025

The USPTO Director vacated the board’s decision to institute inter partes review based on an erroneous application of the Fintiv factors. Specifically, the Director found that the board placed too much emphasis on Petitioner’s Sotera stipulation, and not enough emphasis on the investment in the parallel litigation. Weighing the factors as a whole, the Director determined that institution should be denied.

...

Read More

IP Newsflash

May 9, 2025

In an institution decision following the USPTO’s withdrawal of its Fintiv Memo, the board addressed discretionary denial of an IPR under Fintiv in view of a parallel ITC investigation. The board noted it would not consider the now-rescinded June 2022 memo from then-director Vidal which instructed that the PTAB would not deny institution of an IPR or PGR under Fintiv when the request is based on a parallel ITC investigation. The board conducted a Fintiv analysis in view of the ITC investigation, but ultimately determined that discretionary denial was not warranted in this particular situation.

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.